Background and Aims Immunotherapy with PD-1 inhibitors combined with tyrosine kinase
inhibitors (TKIs) has been proven to be effective against advanced hepatocellular carcinoma …

Background Combined treatment with tyrosine kinase inhibitors (TKI) plus anti-PD-1
antibodies showed high anti-tumor efficacy and made conversion resection possible for …

Background Recent research has shown that selected patients with initially unresectable
hepatocellular carcinoma (HCC) are able to achieve conversion to resectable disease …

Background: Combined therapy with tyrosine kinase inhibitors (TKIs) and anti-PD-1
antibodies has shown high tumor response rates for patients with unresectable …

Background Immunotherapy‐antiangiogenesis combination therapy has achieved excellent
survival outcomes in hepatocellular carcinoma (HCC) in clinical trials. However, the …

Background Optimal strategies for advanced hepatocellular carcinoma (HCC) tumors, such
as those with vascular tumor thrombus and those with extrahepatic metastases are unclear …

Background A combination of tyrosine kinase inhibitors (TKIs) and anti-PD-1 antibodies with
local regional therapy has elicited yield substantial clinical benefits in patients who have …

Hepatocellular carcinoma (HCC) has been the fifth most common malignancy worldwide
and is the second most common cause of tumor-related mortality globally. In China, a high …

Background Previous studies have explored cancer immunotherapy with radiotherapy or
anti-angiogenic therapy, but no trials have reported a triple therapy approach. This study …

Introduction: The actual rate of conversion surgery and its prognostic advantages remain
unclear. This study aimed to assess the outcomes of salvage surgery after conversion …